Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189314 | 1.00 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1CDK5 | |
| SCHEMBL7132308 | 0.97 | LIPA (0.40) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL497572 | 0.97 | LIPA (0.40) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL15261953 | 0.97 | LIPA (0.40) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL2568051 | 0.97 | LIPA (0.40) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL23885014 | 0.94 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL6814313 | 0.94 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL11324326 | 0.94 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL10452360 | 0.94 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1LMNA | |
| SCHEMBL6941115 | 0.94 | LIPA (0.39) | LIPAGAACYP11B2CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | claimed |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-115947678-A | Synthetic method of stable isotope 2H (D) labeled 25-hydroxy vitamin D2 | 成都诺森医学检验有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230002366-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-01-05 | — | — | US | disclosed |
| US-11420962-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2022-08-23 | — | — | US | disclosed |
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | disclosed |
| CN-102413876-A | Pharmaceutical compositions and methods for treating tuberculosis | ORGANON NV | 2012-04-11 | — | — | CN | disclosed |
| US-20120058977-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2012-03-08 | — | — | US | disclosed |
| CN-101541330-A | Use of vitamin D compounds for preventing adhesions | BIOXELL SPA (IT) | 2009-09-23 | — | — | CN | disclosed |
| EP-0823423-B1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| US-6090853-A | Fungicidally active carboxylic acid amides | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-18 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-5534653-A | FUNGICIDES, PESTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-09 | — | — | US | disclosed |
| EP-0364843-A2 | Isomers of trimethylbicyclo[4.3.0] nonane derivatives | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058977-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | FNTB, DCXR, TREH | LIPA 138/4885GAA 140/4885CYP11B2 814/4885 |
| US-20230002366-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | IL1B, IL1A, LTB4R | LIPA 1917/4885GAA 4727/4885CYP11B2 94/4885 |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | POLRMT, LIPC, POLM | LIPA 9/4885GAA 420/4885CYP11B2 3874/4885 |
| US-11420962-B2 | Indene derivatives useful in treating pain and inflammation | IL1B, IL1A, LTB4R | LIPA 1917/4885GAA 4727/4885CYP11B2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.